natgillin/translations-raw huggingface dataset:
In CRYSTAL, the proportion of subjects who experienced a complete resolution (defined as 100% resolution of at least one target tophus and no single tophus showing progression) of ≥1 target tophus was higher in the group treated with Zurampic 200 mg in combination with febuxostat compared with placebo in combination with febuxostat, although the difference was not statistically different (26% compared with 21%).
V študiji CRYSTAL je bil delež bolnikov s popolnim izginotjem (opredeljenim kot 100 % izginotje vsaj enega ciljnega tofa in brez napredovanja katerega koli tofa) ≥ 1 ciljnega tofa večji s kombinacijo 200 mg zdravila Zurampic in febuksostata kot s kombinacijo placeba in febuksostata, a razlika ni bila statistično značilna (26 % v primerjavi z 21 %).
In CT-AMT-011- 02 faeces was also collected.
V študiji CT-AMT-011- 02 so odvzeli tudi blato.
In CURE, the major bleeding event rate for clopidogrel + ASA was dose-dependent on ASA (<100 mg: 2.6%; 100-200 mg: 3.5%; >200 mg: 4.9%) as was the major bleeding event rate for placebo + ASA (<100 mg: 2.0%; 100-200 mg: 2.3%; >200 mg: 4.0%).The risk of bleeding (life-threatening, major, minor, other) decreased during the course of the trial: 0-1 months
V študiji CURE je bil delež dogodkov z velikimi krvavitvami za skupino, ki je jemala klopidogrel in ASA, odvisen od odmerka ASA (< 100 mg: 2,6%%; 100–200 mg: 3,5%%; > 200 mg: 4,9%%), kakor tudi delež velikih krvavitev za skupino, ki je jemala placebo in ASA (< 100 mg: 2%%; 100–200 mg: 2,3%%; >200 mg: 4%%).
In CURE, the major bleeding event rate for clopidogrel+ASA was dose-dependent on ASA (100mg: 2.6%; 100-200mg: 3.5%; 200mg: 4.9%) as was the major bleeding event rate for placebo+ASA (100mg: 2.0%; 100-200mg: 2.3%; 200mg: 4.0%).
V CURE je bil delež dogodkov z velikimi krvavitvami za klopidogrel in ASA odvisen od odmerka ASA (< 100 mg: 2,6 %; 100-200 mg: 3,5 %; > 200 mg: 4,9 %), kakor tudi delež velikih krvavitev za placebo in ASA (< 100 mg: 2,0 %; 100-200 mg: 2,3 %; > 200 mg: 4,0 %).
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery .
V CURE število velikih krvavitev s klopidogrelom in ASA ni bilo prekoračeno v 7 dneh po koronarni premostitveni operaciji pri bolnikih, ki so prenehali z zdravljenjem več kot 5 dni pred kirurškim posegom (4,4 % klopidogrel in ASA proti 5,3 % placebo in ASA).
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery .
V CURE število velikih krvavitev s klopidogrelom in ASA ni bilo prekoračeno v 7 dneh po koronarni premostitveni operaciji pri bolnikih, ki so prenehali z zdravljenjem več kot 5 dni pred kirurškim posegom .
In Cushing’s disease patients, pasireotide demonstrates linear and time-independent pharmacokinetics in the dose range of 0.3 mg to 1.2 mg twice a day.
Farmakokinetika pasireotida je pri bolnikih s Cushingovo boleznijo v obsegu odmerkov od 0,3 mg do 1,2 mg dvakrat na dan linearna in neodvisna od časa.
In Cushing’s disease, the tumour causes overproduction of a hormone called ACTH, which in turn stimulates the production of too much cortisol (a hormone also known as the ‘stress hormone’ because it is released in response to stress).
Pri Cushingovi bolezni tumor povzroča čezmerno tvorjenje hormona ACTH, ta pa spodbuja tvorjenje prevelike količine kortizola (hormona, znanega kot „stresni hormon“, ker ga telo sprošča kot odziv na stres).
In Cycle 1, the overall incidence of IRRs was higher in patients with Gazyvaro and bendamustine (G+B) (55%) compared to patients receiving B alone (42%) (with Grade 3-5 IRRs reported in 9% and 2%, respectively and no fatal events reported).
Skupna incidenca reakcij, povezanih z infuzijo, je bila v 1. ciklusu večja v skupini, ki je prejemala kombinacijo zdravila Gazyvaro in bendamustina (G + B), (55 %), kot v skupini, ki je prejemala bendamustin (B) sam (42 %) (o reakcijah, povezanih z infuzijo, 3. do 5. stopnje so poročali pri 9 % bolnikov iz skupine G + B v primerjavi z 2 % bolnikov iz skupine B, o smrtnih izidih niso poročali).
In cycles 1 and 2, Empliciti is administered once weekly on days 1, 8, 15, and 22.
Pri 1. in 2. ciklu boste zdravilo Empliciti prejeli enkrat na teden na 1., 8., 15. in 22. dan.
In cycles 1 to 4, Bortezomib Accord is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
V krogih 1 do 4 se zdravilo Bortezomib Accord daje dvakrat na teden, 1., 4., 8., 11., 22., 25., 29. in 32. dan.
In cycles 1 to 4, bortezomib is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
V krogih 1 do 4 se bortezomib daje dvakrat na teden, 1., 4., 8., 11., 22., 25., 29. in 32. dan.
In cycles 1 to 4, VELCADE is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
V krogih 1 do 4 se zdravilo VELCADE daje dvakrat na teden, 1., 4., 8., 11., 22., 25., 29. in 32. dan.
In cycles 1 to 4, VELCADE is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
V krogih 1 do 4 se zdravilo VELCADE daje dvakrat na teden,1., 4., 8., 11., 22., 25., 29. in 32. dan.
In Cycles 1-4, Bortezomib Accord is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
V krogih 1-4 se zdravilo Bortezomib Accord daje dvakrat na teden, na 1., 4., 8., 11., 22.,
In Cycles 1-4, VELCADE is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
V krogih 1-4 se zdravilo VELCADE daje dvakrat na teden, na 1., 4., 8., 11., 22., 25.,
In cycles 3 and beyond, Empliciti is administered once every 2 weeks on days 1 and 15.
Pri 3. in kasnejših ciklih boste zdravilo Empliciti prejeli enkrat na vsaka 2 tedna na 1. in 15. dan.
In cycles 5 to 9, Bortezomib Accord is administered once weekly on days 1, 8, 22 and 29.
V krogih 5 do 9 pa enkrat na teden, 1., 8., 22. in 29. dan.
In cycles 5 to 9, bortezomib is administered once weekly on days 1, 8, 22 and 29.
V krogih 5 do 9 pa enkrat na teden, 1., 8., 22. in 29. dan.
In cycles 5 to 9, Bortezomib SUN is administered once weekly on days 1, 8, 22 and 29.
V krogih 5 do 9 pa enkrat na teden, 1., 8., 22. in 29. dan.
In cycles 5 to 9, VELCADE is administered once weekly on days 1, 8, 22 and 29.
V krogih 5 do 9 pa enkrat na teden, 1., 8., 22. in 29. dan.
In Cycles 5-9, Bortezomib Accord is administered once weekly on days 1, 8, 22 and 29.
25., 29. in 32. dan, v krogih 5-9 pa enkrat na teden, na 1., 8., 22. in 29. dan.
In Cycles 5-9, Bortezomib SUN is administered once weekly on days 1, 8, 22 and 29.
V krogih 5 do 9 pa enkrat na teden, 1., 8., 22. in 29. dan.
In Cycles 5-9, VELCADE is administered once weekly on days 1, 8, 22 and 29.
29. in 32. dan, v krogih 5-9 pa enkrat na teden, na 1., 8., 22. in 29. dan.
In CYP2C9 poor metabolizers, co-administration of CYP3A4 inhibitors may increase systemic concentration of ospemifene to a larger extent.
Pri bolnicah s slabo presnovo s CYP2C9 lahko sočasno dajanje zaviralcev CYP3A4 v večjem obsegu poveča sistemsko koncentracijo ospemifena.
In CYP2D6 poor metabolisers, concomitant use of potent inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers.
Pri osebah, ki slabo presnavljajo s CYP2D6 lahko sočasna uporaba z močnimi zaviralci CYP3A4 povzroči večjo koncentracijo aripiprazola v plazmi kot pri osebah, ki dobro presnavljajo s CYP2D6.
In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolisers (see section 4.2).
Pri osebah, ki slabo presnavljajo s CYP2D6 lahko sočasna uporaba z močnimi zaviralci CYP3A4 povzroči večjo koncentracijo aripiprazola v plazmi kot pri osebah, ki dobro presnavljajo s CYP2D6.
In cystic fibrosis these secretions become thick and cause blockage.
Pri cistični fibrozi se tovrstni izločki zgostijo in povzročajo zaporo.
In cystic fibrosis, the patient’s lungs produce too much thick mucus, which allows bacteria to grow more easily.
Pri cistični fibrozi v bolnikovih pljučih nastaja preveč goste sluzi, ki bakterijam omogoča lažjo rast.
In cytopenic dogs, there were no adverse events on progenitor and proliferating cells in the bone marrow.
Pri psih z izraženo citopenijo ni bilo neželenih učinkov na progenitorne in proliferirajoče celice v kostnem mozgu.
In de novo kidney and liver transplant patients AUC0-24 of tacrolimus for Advagraf on Day 1 was 30% and 50% lower respectively, when compared with that for the immediate release capsules (Prograf at equivalent doses.
V primerjavi z uporabo ekvivalentnih odmerkov kapsul s takojšnjim sproščanjem (zdravilo Prograf) je bila vrednost AUC0-24 takrolimusa na 1. dan uporabe zdravila Advagraf pri bolnikih z na novo presajeno ledvico manjša za 30 %, pri bolnikih z na novo presajenimi jetri pa za 50 %.
In debilitated or malnourished patients the initial and maintenance dosage should be conservative and careful dose titration is required to avoid hypoglycaemic reactions.
Pri oslabelih in podhranjenih bolnikih mora biti začetno in vzdrževalno odmerjanje konzervativno; odmerek je treba skrbno prilagoditi, da bi preprečili hipoglikemične reakcije.
In dementia, DaTSCAN has been studied in one main study involving 288 adults who had been diagnosed with dementia with Lewy bodies or Alzheimer’s disease, or another form of dementia.
Pri demenci so zdravilo DaTSCAN proučevali v eni glavni študiji pri 288 odraslih bolnikih z diagnosticirano demenco z Lewyjevimi telesci ali Alzheimerjevo boleznijo, ali katero drugo obliko demence.
In depressed patients, treatment with Thymanax 25 mg increased slow wave sleep without modification of REM (Rapid Eye Movement) sleep amount or REM latency.
Pri bolnikih z depresijo je zdravljenje z zdravilom Thymanax v odmerku 25 mg podaljšalo spanje s počasnimi valovi, brez vpliva na fazo spanja REM (Rapid Eye Movement) ali na čas do njenega nastopa.
In depressed patients, treatment with Valdoxan 25 mg increased slow wave sleep without modification of REM (Rapid Eye Movement) sleep amount or REM latency.
Pri bolnikih z depresijo je zdravljenje z zdravilom Valdoxan v odmerku 25 mg podaljšalo spanje s počasnimi valovi, brez vpliva na fazo spanja REM (Rapid Eye Movement) ali na čas do njenega nastopa.
In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, hyperkalaemia (≥ 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group and 26.3% of the patients in the placebo group.
Pri diabetičnih bolnikih z visokim krvnim tlakom s kronično ledvično insuficienco in izraženo proteinurijo, se je hiperkaliemija (≥ 5,5 mEq/l) pojavila pri 46,3% bolnikov, ki so dobivali irbesartan in pri 26,3% bolnikov v placebo skupini
In diabetic hypertensive patients with microalbuminuria and normal renal function, hyperkalaemia (≥ 5.5 mEq/L) occurred in 29.4% of the patients in the irbesartan 300 mg group and 22% of the patients in the placebo group.
Pri diabetičnih bolnikih z visokim krvnim tlakom z mikroalbuminurijo in normalno ledvično funkcijo, se je hiperkaliemija (≥ 5,5 mEq/l) pojavila pri 29,4% bolnikov, ki so prejemali 300 mg irbesartana in pri 22% bolnikov v skupini s placebom.
In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in excess of placebo.
Pri diabetičnih bolnikih z visokim krvnim tlakom z mikroalbuminurijo in normalnim delovanjem ledvic, so poročali o ortostatski omotici in ortostatski hipotenziji pri 0,5% bolnikov (to je občasno), kar je več kot pri placebu.
In diabetic macular oedema, Lucentis was more effective at improving vision than its comparators.
Zdravilo Lucentis je bilo pri izboljšanju vida pri makularnem edemu, ki ga povzroča sladkorna bolezen, učinkovitejše od primerjalnih zdravil.
in disposable pen
vložek (steklen) v peresniku za enkratno uporabo
in disposable pen cartridge (glass)
viala (steklena)
in disposable pen cartridge (glass)
vložek (steklen)
in disposable pen cartridge (glass)
vložek (steklen) v peresniku za enkratno uporabo
in disposable pens cartridge (glass)
vložek (steklen) v peresniku za enkratno uporabo
in divided doses over 2-5 days
v razdeljenih odmerkih 2–5 dni
In Docetaxel Accord 160 mg/8 ml vial the concentration of docetaxel is 20 mg/ml.
V Docetaksel Accord 160 mg/8 ml vialah je koncentracija docetaksela 20 mg/ml.
In Docetaxel Accord 80 mg/4 ml vial the concentration of docetaxel is 20 mg/ml.
V Docetaksel Accord 80 mg/4 ml vialah je koncentracija docetaksela 20 mg/ml.
In DOCETAXEL KABI 120 mg/6 ml vial the concentration of docetaxel is 20 mg/ml.
V viali, ki vsebuje zdravilo DOCETAKSEL KABI 120 mg/6 ml, je koncentracija docetaksela 20 mg/ml.
In DOCETAXEL KABI 160 mg/8 ml vial the concentration of docetaxel is 20 mg/ml.
V viali, ki vsebuje zdravilo DOCETAKSEL KABI 160 mg/8 ml, je koncentracija docetaksela 20 mg/ml.
In DOCETAXEL KABI 180 mg/9 ml vial the concentration of docetaxel is 20 mg/ml.
V viali, ki vsebuje zdravilo DOCETAKSEL KABI 180 mg/9 ml, je koncentracija docetaksela 20 mg/ml.
In DOCETAXEL KABI 20 mg/1 ml vial the concentration of docetaxel is 20 mg/ml.
V viali, ki vsebuje zdravilo DOCETAKSEL KABI 20 mg/1 ml, je koncentracija docetaksela 20 mg/ml.
In DOCETAXEL KABI 80 mg/4 ml vial the concentration of docetaxel is 20 mg/ml.
V viali, ki vsebuje zdravilo DOCETAKSEL KABI 80 mg/4 ml, je koncentracija docetaksela 20 mg/ml.
In Docetaxel Winthrop 160 mg/8 ml vial the concentration of docetaxel is 20 mg/ml.
V viali, ki vsebuje zdravilo Docetaxel Winthrop 160 mg/8 ml, je koncentracija docetaksela 20 mg/ml.
In Docetaxel Winthrop 160 mg/8 ml vial the concentration of docetaxel is 20 mg/ml.
V zdravilu Docetaxel Winthrop 160 mg/8 ml vialah je koncentracija docetaksela 20 mg/ml.
In Docetaxel Winthrop 20 mg /1 ml vial the concentration of docetaxel is 20 mg/ml.
V Docetaxel 20 mg/1 ml vialah je koncentracija docetaksela 20 mg/ml.
In Docetaxel Winthrop 20 mg/1 ml vial the concentration of docetaxel is 20 mg/ml.
V viali, ki vsebuje zdravilo Docetaxel Winthrop 20 mg/1 ml, je koncentracija docetaksela 20 mg/ml.
In Docetaxel Winthrop 80 mg /4 ml vial the concentration of docetaxel is 20 mg/ml.
V zdravilu Docetaxel Winthrop 80 mg/4 ml vialah je koncentracija docetaksela 20 mg/ml.
In Docetaxel Winthrop 80 mg/4 ml vial the concentration of docetaxel is 20 mg/ml.
V viali, ki vsebuje zdravilo Docetaxel Winthrop 80 mg/4 ml, je koncentracija docetaksela 20 mg/ml.
In dogs exposed to 4% sevoflurane for 3 hours, mean peak maximum serum fluoride concentrations of 20.0  4.8 mol/l have been observed after 3 hours of anaesthesia.
Pri psih, izpostavljenih 4-odstotnemu sevofluranu 3 ure dolgo, so opazovali srednji vrh najvišjih serumskih koncentracij fluorida 20,0 ± 4,8 µmol/l po 3 urah anestezije.
In dogs given tadalafil daily for 6 to 12 months at doses of 25 mg/kg/day (resulting in at least a 3-fold greater exposure [range 3.7 – 18.6] than seen in humans given a single 20 mg dose) and above, there was regression of the seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some dogs.
Pri psih, ki so tadalafil prejemali dnevno 6 do 12 mesecev v odmerkih 25 mg/kg/dan (kar pomeni vsaj 3-krat večjo izpostavitev [razpon 3,7-18,6], kot je bila opažena pri ljudeh pri enkratnem odmerku 20 mg) in več, je prišlo do regresije epitela semenskih cevk, kar je pri nekaterih psih povzročilo zmanjšanje spermatogeneze.
In dogs given tadalafil daily for 6 to 12 months at doses of 25 mg/kg/day (resulting in at least a 3-fold greater exposure [range 3.7 – 18.6] than seen in humans given a single 20 mg dose) and above, there was regression of the seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some dogs.
Pri psih, ki so tadalafil prejemali dnevno 6 do 12 mesecev v odmerkih 25 mg/kg/dan (kar pomeni vsaj 3-krat večjo izpostavitev [razpon 3,7– 18,6], kot je bila opažena pri ljudeh pri enkratnem odmerku 20 mg) in več, je prišlo do regresije epitela semenskih cevk, kar je pri nekaterih psih povzročilo zmanjšanje spermatogeneze.
In dogs given tadalafil daily for 6 to 12 months at doses of 25 mg/kg/day (resulting in at least a 3-fold greater exposure [range 3.7-–-18.6] than seen in humans given a single 20 mg dose) and above, there was regression of the seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some dogs.
Pri psih, ki so tadalafil prejemali dnevno 6 do 12 mesecev v odmerkih 25 mg/kg/dan (kar pomeni vsaj 3-krat večjo izpostavitev [razpon 3,7-18,6], kot je bila opažena pri ljudeh pri enkratnem odmerku 20 mg) in več, je prišlo do regresije epitela semenskih cevk, kar je pri nekaterih psih povzročilo zmanjšanje spermatogeneze.
In dogs it is applied between the shoulder blades at the bottom of the dog’s head, but for large dogs (above 25 kg) the product should be applied in 3 or 4 spots along the dog’s back, whilst it is standing, from between its shoulder blades to the base of its tail.
Pri psih se zdravilo nanese na zatilje med lopaticama, pri večjih psih (težjimi od 25 kg) pa na tri ali štiri predele vzdolž hrbta, od lopatic do korena repa, pri čemer naj žival stoji.
in dogs less than 18 months of age. if overweight or obesity in your dog is caused by a concomitant systemic disease such as hypothyroidism (this is due to a malfunction of the thyroid gland) or hyperadrenocorticism.(this is due to a malfunction of the adrenal gland).
je mlajši od 18 mesecev; čezmerno težo ali adipoznost povzroča sočasna sistemska bolezen, kot je hipotiroidizem (ki je posledica okvarjenega delovanja ščitnice) ali hiperadrenokorticizem (ki je posledica okvarjenega delovanja nadledvične žleze).
In dogs only, infusion reactions characterised by skin swelling and/or redness (not associated with the injection site), mucosal pallor, salivation, vomiting, sedation, and modest declines in blood pressure and increases in heart rate were observed in a dose-dependent manner.
Samo pri psih so po injiciranju zabeležili reakcije v obliki oteklin in/ali rdečice po koži (nevezano na mesto injiciranja), bledico sluznice, slinjenje, bruhanje, sedacijo, zaznali pa so pa tudi zmerne odklone krvnega tlaka in povišanje srčnega utripa v odvisnosti od odmerka.
In dogs the oral administration of difloxacin at up to 5 times the recommended dose rate for 30 days did not result in any adverse reactions.
Peroralno dajanju petkrat večjih odmerkov difloksacina v obdobju 30 dni ni povzročilo nastanka neželenih učinkov.
In dogs treated at the therapeutic dose for ten consecutive days, serum cortisol levels decreased from five days onward and returned to normal values within ten days after the end of treatment.
Pri psih, ki so bili s terapevtskim odmerkom zdravljeni deset zaporednih dni, se je raven serumskega kortizola zmanjševala od petega dneva naprej in se vrnila v normalne vrednosti v desetih dneh po koncu zdravljenja.
In dogs with a bodyweight of less than 15 kg accurate dosing is not always possible.
Pri psih s telesno maso pod 15 kg točno odmerjanje ni vedno možno.
In dogs with non- resectable mast cell tumours, Grade 2 or 3, expressing a mutated tyrosine kinase c-kit receptor, treatment with Masivet showed a significantly longer Time-to-Tumour Progression (TTP) with a median of 241 days as compared to 83 days for placebo.
Pri psih z neodstranljivimi tumorji mastocitov (stopnje 2 ali 3) z izraženim mutiranim receptorjem c-KIT tirozin kinaze je zdravljenje z zdravilom Masivet izkazalo bistveno daljši čas do napredovanja tumorja (TTP) s srednjo vrednostjo 241 dni v primerjavi s 83 dnevi za placebo.
In dogs, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours after dosing and is most likely caused by a local effect on the small intestines.
Neželeni učinek, ki so ga pogosto opazili pri psih, je bruhanje, ki se pojavi v prvih 48 urah po dajanju zdravila in ga najverjetneje povzroči lokalni učinek na tanko črevo.
In dogs, a slight increase in resorptions was seen; however, all foetuses in medication–treated animals were viable, and the incidence of live foetuses in medication– treated animals was comparable to that in controls.
Pri psih so opazili rahlo povečanje resorpcije, vendar so bili vsi plodi zdravljenih živali sposobni za življenje in je bila pojavnost živih plodov zdravljenih živali primerljiva s tisto v kontrolni skupini.
In dogs, adverse reactions are associated with neurological signs caused by metabolites of the active substance.
Neželeni učinki pri psih se odražajo v obliki nevroloških simptomov, ki jih povzročajo razkrojni produkti aktivne učinkovine.
In dogs, an increase in liver enzymes after long-term treatment with the tablets is common (affecting 1 to 10 animals in 100).
Pri psih se po dolgotrajnejšem zdravljenju s tabletami pogosto pojavi povišanje jetrnih encimov (ki prizadene 1 do 10 živali od 100).
In dogs, in very rare cases, haemorrhagic diarrhoea, haematemesis, and gastrointestinal ulceration have been reported.
Pri psih so zelo redko poročali o hemoragični driski, hematemezi in razjedi prebavil.
In dogs, Meloxidyl is used as an oral suspension to relieve inflammation and pain in musculo- skeletal disorders.
Pri psih se zdravilo Meloxidyl uporablja kot peroralna suspenzija za lajšanje vnetja in bolečin pri kostno-mišičnih obolenjih.
In dogs, Onsior tablets are used for the treatment of pain and inflammation associated with chronic osteoarthritis (a long-term disease causing pain in the joints).
Pri psih se tablete zdravila Onsior uporabljajo za zdravljenje bolečin in vnetij pri kroničnem osteoartritisu (dolgotrajni bolezni, ki povzroča bolečine v sklepih).
In dogs, Rheumocam is used to reduce post-operative pain and inflammation following orthopaedic (e.g. fracture operation) and soft tissue surgery.
Pri psih se zdravilo Rheumocam uporablja za blažitev pooperativnih bolečin in vnetja po ortopedskih kirurških posegih (npr. po operaciji zaradi zloma kosti) in kirurških posegih na mehkih tkivih.
In dogs, robenacoxib was in vitro approximately 140 fold selective for COX-2 (IC50 0.04 μM) as compared to COX-1 (IC50 7.9 μM).
Pri psih je bila selektivnost robenakoksiba in vitro približno 140-krat večja za COX-2 (IC50 0,04 μM) kot za COX-1 (IC50 7,9 μM).
In dogs, slight inflammatory responses were observed following chronic high dose administration of ambrisentan at exposures greater than 20–fold that observed in patients.
Pri psih so pri dolgotrajni uporabi visokih odmerkov ambrisentana pri izpostavljenosti, ki je bila več kot 20-krat večja od izpostavljenosti bolnika, poročali o blagih vnetnih spremembah.
In dogs, the volume of distribution (VDss) is 3.8 l/kg.
Pri psih znaša distribucijski volumen 3.1 l/kg.
In dogs, these adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
Pri psih so našteti neželeni učinki najpogostnejši prvi teden zdravljenja, so večinoma prehodni in po končanem zdravljenju minejo, vendar so lahko v zelo redkih primerih tudi resni ali smrtno nevarni.
In dogs, these side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
pojavijo v prvem tednu zdravljenja, so večinoma prehodni in po končanem zdravljenju izginejo, vendar so lahko v zelo redkih primerih tudi resni ali smrtno nevarni.
In dogs, these side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
Pri psih se našteti neţeleni škodljivi učinki preteţno pojavijo v prvem tednu zdravljenja, so večinoma prehodni in po končanem zdravljenju minejo, vendar so lahko v zelo redkih primerih tudi resni ali smrtno nevarni.